ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

ElectroCore reports robust Q3 revenue growth, eyes VA channel expansion

ElectroCore Inc delivered strong revenue growth and improved financial performance in Q3 2024, driven by key product sales and customer expansion.
While facing challenges in certain product lines and overall net loss, the company's strategic focus on growth areas and cost management bode well for the future.
Opportunities in new purchase orders, VA channel expansion, and brand development position ElectroCore for continued success and market advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

electroCore Expands Intellectual Property Portfolio

electroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.22 per share a year ago.

ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

Record full year 2023  net sales of $ 16.0 million increased 87%  over $8.6  million for the full year 2022

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company's proprietary nVNS technology platform that is embodied in its gammaCore product.

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

electroCore, Inc. (NASDAQ:ECOR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dan Goldberger – Chief Executive Officer Brian Posner – Chief Financial Officer Conference Call Participants Destiny Hance – Ladenburg Thalmann Ramakanth Swayampakula – H.C. Wainwright Nick Sherwood – Maxim Group, LLC Walter Schenker – MAZ Partners Operator Greetings, and welcome to the electroCore Third Quarter 2023 Earnings Conference Call.

electroCore, Inc. (ECOR) Q3 2023 Earnings Call Transcript

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million  Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2023 financial results and provided an operational update.

electroCore Announces Third Quarter 2023 Financial Results

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.

electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom's National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026.

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS.

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.

electroCore to Announce Third Quarter Financial Results on Wednesday, November 8

ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.

electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference

Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.

electroCore to Participate in the LD Micro Main Event XVI Conference

ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.

electroCore to Present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual Conference

ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company's 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore.

electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. (NASDAQ:ECOR ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Daniel Goldberger - CEO & Director Brian Posner - CFO & Corporate Secretary Conference Call Participants John Vandermosten - Zacks Swayampakula Ramakanth - H.C. Wainwright & Co. Nick Sherwood - Maxim Tyler Bussian - Brookline Capital Markets Operator Greetings, and welcome to the electroCore Second Quarter 2023 Earnings Conference Call.

electroCore, Inc. (ECOR) Q2 2023 Earnings Call Transcript

Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKAWAY, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced second quarter 2023 financial results and provided an operational update.

electroCore Announces Second Quarter 2023 Financial Results

ROCKAWAY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

electroCore to Announce Second Quarter Financial Results on Wednesday, August 9

ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $4.4125 per share and related warrant. The warrants will be exercisable commencing six months after the date of issuance at a price of $4.35 per share and will expire five years after they first become exercisable.

News for ElectroCore Inc Stock (ECOR)